Lonnie Dahm
About Lonnie Dahm
Lonnie Dahm is the Executive Director and Head of Nonclinical Safety Evaluation at Alkermes, with extensive experience in pharmacology and toxicology.
Current Title and Role
Lonnie Dahm currently holds the position of Executive Director and Head of Nonclinical Safety Evaluation at Alkermes in Waltham, MA. He has been responsible for leading nonclinical safety assessment for over 14 years. His role encompasses overseeing global regulatory interactions for Alkermes' Discovery and Development programs.
Previous Employment at Pfizer
Before joining Alkermes, Lonnie Dahm worked at Pfizer in Groton, CT, where he held the position of Senior Director. His tenure at Pfizer spanned 12 years, from 1997 to 2009. During this period, he gathered significant experience in the pharmaceutical industry, contributing to various nonclinical safety evaluation projects.
Previous Employment at Procter & Gamble Pharmaceuticals
Lonnie Dahm began his career as a Research Scientist at Procter & Gamble Pharmaceuticals in Mason, OH. He worked there for 3 years, from 1994 to 1997. This role helped him develop a solid foundation in research and safety evaluation in the pharmaceutical sector.
Educational Background
Lonnie Dahm studied Biochemistry at Emory University School of Medicine, completing a Postdoctoral program from 1990 to 1994. He earned a Ph.D. in Pharmacology and Toxicology from Michigan State University, studying from 1984 to 1990. Additionally, he holds a Bachelor's Degree in Toxicology from Philadelphia College of Pharmacy and Science, completing his undergraduate studies from 1980 to 1984.
Experience in Nonclinical Safety Evaluation
With extensive experience in nonclinical safety evaluation spanning multiple decades, Lonnie Dahm has been instrumental in ensuring the safety of various pharmaceutical products. His background in pharmacology and toxicology provides a robust framework for leading safety assessments and regulatory interactions for Alkermes' development programs.